Ignite Creation Date:
2024-05-05 @ 4:41 PM
Last Modification Date:
2024-10-26 @ 9:23 AM
Study NCT ID:
NCT00299767
Status:
COMPLETED
Last Update Posted:
2016-05-11
First Post:
2006-03-03
Brief Title:
Phase I Study of Sequential Cord Blood Transplants
Sponsor:
Massachusetts General Hospital
Organization:
Massachusetts General Hospital
Study Overview
Official Title:
Phase I Study of Sequential Cord Blood Transplants
Status:
COMPLETED
Status Verified Date:
2016-05
Last Known Status:
None
Delayed Posting:
No
If Stopped, Why?:
Not Stopped
Has Expanded Access:
False
If Expanded Access, NCT#:
N/A
Has Expanded Access, NCT# Status:
N/A
Acronym:
None
Brief Summary:
The purpose of this study is to determine the safety of sequential cord blood transplantation 2 cord blood units for patients who have diseases that are capable of being cured by allogeneic stem cell transplant but do not have a matched family or volunteer unrelated donor
Detailed Description:
Eligible patients will receive conditioning therapy with fludarabine 30 mgm2day x 6 days melphalan 100 mgm2day x 1 day rabbit antithymocyte globulin 15 mgkgday x 4 days GVHD prophylaxis will consist of cyclosporine starting on day -1 and mycophenolate mofetil starting on day 0 Sequential cord blood units will be infused on Day 0
Study Oversight
Has Oversight DMC:
None
Is a FDA Regulated Drug?:
None
Is a FDA Regulated Device?:
None
Is an Unapproved Device?:
None
Is a PPSD?:
None
Is a US Export?:
None
Is an FDA AA801 Violation?:
None